Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Countries Call For Health Technology Assessments Of COVID-19 Products

Executive Summary

Value assessments of COVID-19 monoclonal antibodies should inform pricing decisions, says cross country coalition.

You may also be interested in...



Coronavirus Notebook: CEPI Calls For Reduced-Dose Booster Trials, Regeneron’s Ronapreve Filed In EU

EU health ministers are discussing booster and additional vaccines as well as COVID-19-related medicines shortages, and England is to offer approved vaccines to clinical trialists to ease international travel.

UK Approves Regeneron/Roche MAb Cocktail For COVID-19

The UK has pipped the EU to the post in granting a marketing authorization to what the health secretary describes as “a significant addition to our armoury to tackle COVID-19.”

Brazilian HTA To Adopt Cost-Effectiveness Thresholds

Brazil’s health technology assessment institute is to incorporate cost-effectiveness thresholds into its decision making.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel